This is a preview of subscription content, log in via an institution to check access.
References
Berndt, E.R. & Aitken, M.L. Int. J. Econ. Bus. 18, 177–201 (2011).
Berndt, E.R., Conti, R.M., Murphy, S. J. The landscape of US generic prescription drug markets, 2004-2016. (Working paper no. 23640) (National Bureau of Economics, Cambridge, 2017).
US Government Accountability Office. Generic Drugs Under Medicare: Part D Generic Drug Prices Declined Overall, but Some Had Extraordinary Price Increases (US GAO, Washington, DC, 2016)
Tenn, S. & Wendling, B.W. Rev. Econ. Stat. 96, 214–228 (2014).
Olson, L.M. & Wendling, B.W. The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period (Working paper no. 317) (FTC Bureau of Economics, Washington DC, 2013).
Author information
Author notes
Shraddha Chakradhar is Nature Medicine's associate news editor in Boston.
- Shraddha Chakradhar
Roxanne Khamsi is Nature Medicine's chief news editor in New York.
- Roxanne Khamsi
Rights and permissions
About this article
Cite this article
Chakradhar, S., Khamsi, R. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs. Nat Med 23, 1114–1116 (2017). https://doi.org/10.1038/nm1017-1114
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1017-1114
- Springer Nature America, Inc.